For adults over 50 who already navigate the annual ritual of separate flu and COVID shots, the prospect of a single injection covering both pathogens—with antibody protection that actually holds for half a year—represents a meaningful shift in how seasonal respiratory protection might be delivered. The question was never just whether a combined vaccine works; it was whether combining targets forces immune compromises that erode durability.
This Phase 3, observer-blind, randomized controlled trial (NCT06097273) enrolled adults aged 50 and older into two age-stratified cohorts: Cohort A (≥65 years) and Cohort B (50–64 years), each randomized 1:1 to receive mRNA-1083 at a 40 µg dose plus placebo, or age-appropriate licensed comparator vaccines for influenza and COVID-19 separately. The primary endpoints focused on noninferiority via hemagglutination inhibition (HAI) titers for all vaccine-matched influenza strains and SARS-CoV-2 pseudovirus neutralizing antibody (PsVNA) responses at Day 29. Through Day 181, influenza HAI titers remained maintained and were broadly comparable to—or exceeded—those from licensed comparators. SARS-CoV-2 neutralizing antibody levels stayed higher in the mRNA-1083 arm than comparators across the full six-month window. Reactogenicity was predominantly Grade 1–2, with no vaccination-related serious adverse events or deaths reported.
This trial adds meaningful Phase 3 evidence to Moderna's mRNA-1083 program, which has been building toward a combined respiratory vaccine that could simplify the adult immunization schedule. The durability finding is particularly notable: waning immunity is among the central criticisms of current COVID-19 mRNA boosters, and sustaining superiority over comparators for six months—not just at peak Day 29—addresses that concern directly. That said, antibody titer maintenance is a surrogate endpoint; translating HAI and nAb levels into real-world protection against symptomatic illness or hospitalization requires efficacy data that this immunogenicity-focused report does not yet provide. The 50-plus age bracket is appropriate given the highest burden of severe disease, but extrapolation to younger immunocompetent adults remains premature. As a single-dose, combination platform, mRNA-1083 has genuine public health logistics appeal, though regulatory approval will hinge on the broader efficacy and longer-term safety dataset.